FutureHouse vs Recursion Pharmaceuticals
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
FutureHouse
Eric-Schmidt-backed nonprofit building AI agents to automate scientifi...
Visit
|
Recursion Pharmaceuticals
Publicly traded techbio company (NASDAQ: RXRX) industrialising drug di...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 7.5 / 10 | 7 / 10 |
| Capability | — | — |
| Value for money | — | — |
| Ease of use | — | — |
| ASEAN readiness | — | — |
| API quality | — | — |
| Pricing | Freemium | Enterprise |
| Free tier | Free public web platform and agents (Crow, Falcon, Owl, Robin) plus a free API tier for researchers. | — |
| Paid from | Higher-throughput / commercial use via the Edison Scientific spinout | Partnership / collaboration deals (not a self-serve product) |
| Has API | ✓ | ✗ |
| Open source | ✗ | ✗ |
| Free to use | ✓ | ✗ |
| Users | — | — |
| Founded | 2023 | 2013 |
| Maker | Sam Rodriques, Andrew White | Chris Gibson |
| Verdict | What this is for: Automating literature review, hypothesis generation and multi-step scientific reasoning with citation-grounded AI agents. Who this is for: Academic researchers and scientists in biology, chemistry and... |
What this is for: AI-driven, industrial-scale drug discovery combining large biological datasets, automated experiments and its own supercomputing. Who this is for: Pharmaceutical and biotech partners, plus investors in... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.